CuCl PET Imaging of 4T1-Related Allograft of Triple-Negative Breast Cancer in Mice.
Fiche publication
Date publication
juillet 2022
Journal
Molecules (Basel, Switzerland)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr AVEROUS Gerlinde, Dr BRASSE David, Pr IMPERIALE Alessio
Tous les auteurs :
Latgé A, Boisson F, Ouadi A, Averous G, Thomas L, Imperiale A, Brasse D
Lien Pubmed
Résumé
CuCl is an economic radiotracer for oncologic PET investigations. In the present study, we characterized the uptake of CuCl in vivo by µPET/CT in an allograft 4T1-related mouse model (BALB/c) of advanced breast cancer. F-FDG was used as a comparator. Twenty-two animals were imaged 7-9 days following 4T1-cell implantation inside mammary glands. Dynamic CuCl µPET/CT acquisition or iterative static images up to 8 h p.i. were performed. Animal biodistribution and tumor uptake were first evaluated in vivo by µPET analysis and then assessed on tissue specimens. Concerning F-FDG µPET, a static acquisition was performed at 15 min and 60 min p.i. Tumor CuCl accumulation increased from 5 min to 4 h p.i., reaching a maximum value of 5.0 ± 0.20 %ID/g. Liver, brain, and muscle CuCl accumulation was stable over time. The tumor-to-muscle ratio remained stable from 1 to 8 h p.i., ranging from 3.0 to 3.7. Ex vivo data were consistent with in vivo estimations. The F-FDG tumor accumulation was 8.82 ± 1.03 %ID/g, and the tumor-to-muscle ratio was 4.54 ± 1.11. CuCl PET/CT provides good characterization of the 4T1-related breast cancer model and allows for exploration of non-glycolytic cellular pathways potentially of interest for theragnostic strategies.
Mots clés
18F-FDG, 4T1, 64CuCl2, PET/CT, biodistribution, breast cancer
Référence
Molecules. 2022 07 29;27(15):